Educational dose math only — not medical advice, not a product recommendation, and not a pass/fail on whether a supplement will work for you.
0 100% 150%+

—

Enter label dose

Trial reference

From your label

Per-day total — not per serving unless you take one serving

Enter your label dose — the gauge updates instantly.

Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation.

Educational only — not medical advice. Disclaimer.

Trial floors

Primary

ATLAS trial, branded Mitopure · 500–1,000 mg over 4 months (limited evidence) · Secondary outcomes only — Two doses of branded Mitopure in middle-aged adults for four months. The primary endpoint — peak power output — was not met. Muscle strength rose about 12%, with improvements in peak VO2, six-minute walk, plasma acylcarnitines and CRP as secondary outcomes. Manufacturer-run trial on a specific synthesised preparation.

Other floors

  • Older adults, 1000 mg · 1,000 mg over 4 months (limited evidence) · Primary endpoint missed — Adults 65-90. Both primary endpoints failed — six-minute walk distance and maximal ATP production in hand muscle were no better than placebo. Secondary muscle endurance in two muscles and plasma biomarkers did improve. Safe and well tolerated.

  • Safety and mitochondrial gene signature · 500–1,000 mg over 4 weeks (limited evidence) · Primary endpoint missed — Sedentary older adults. This trial established tolerability and showed the compound reaches muscle and shifts mitochondrial gene expression. There was no strength or performance endpoint at all — it answers "does oral urolithin A do anything in tissue", not "will I be stronger".

Label reading notes

  • Every human trial to date used a synthesised branded preparation (Mitopure). A generic urolithin A powder at the same milligram count is not covered by this evidence.
  • Pomegranate juice or ellagitannin extracts are not equivalent — only some people carry the gut bacteria that convert ellagitannins to urolithin A, which is the reason direct supplementation exists.
  • Shelf comparison is switched off for this ingredient: too few labelled products, and branded versus generic material is not comparable on milligrams alone. Whether it should be comparable is an open question.
  • Across all three trials the prespecified primary endpoints were missed. The human case rests on secondary outcomes.